3D-QSAR CoMFA analysis of C5 substituted pyrrolotriazines as HER2 (ErbB2) inhibitors.

Human cancers are characterized by an up-regulation of some of the RTKs (EGFR and HER2) and have been clinically validated as targets for cancer therapy. C4 and C5 substituted pyrrolotriazines showed dual inhibition of HER2 and EGFR protein tyrosine kinases. To explore the relationship between the structures of the aforementioned classes of molecules and their HER2 inhibition, 3D-QSAR CoMFA analysis have been performed. The developed CoMFA model showed statistically significant results with good predictive ability.

[1]  J. Buolamwini,et al.  Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors. , 2003, Journal of medicinal chemistry.

[2]  J. Fargnoli,et al.  Discovery of the pyrrolo[2,1-f][1,2,4]triazine nucleus as a new kinase inhibitor template. , 2004, Journal of medicinal chemistry.

[3]  Henry Wong,et al.  New C-5 substituted pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases. , 2007, Bioorganic & medicinal chemistry letters.

[4]  A Whitty,et al.  Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases. , 1997, Journal of medicinal chemistry.

[5]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[6]  Hugo Kubinyi,et al.  3D QSAR in drug design : theory, methods and applications , 2000 .

[7]  Wei Kong,et al.  QSAR analysis of tyrosine kinase inhibitor using modified ant colony optimization and multiple linear regression. , 2007, European journal of medicinal chemistry.

[8]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[9]  D. E. Patterson,et al.  Crossvalidation, Bootstrapping, and Partial Least Squares Compared with Multiple Regression in Conventional QSAR Studies , 1988 .

[10]  H. Wiley,et al.  ErbB-2 Amplification Inhibits Down-regulation and Induces Constitutive Activation of Both ErbB-2 and Epidermal Growth Factor Receptors* , 1999, The Journal of Biological Chemistry.

[11]  Henry Wong,et al.  Novel C-5 aminomethyl pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases. , 2007, Bioorganic & medicinal chemistry letters.

[12]  A. Jimeno,et al.  Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. , 2006, Biochimica et biophysica acta.